leadf
logo-loader
viewMGC Pharmaceuticals Ltd

MGC Pharmaceuticals strengthens board and leadership team with strategic biopharma industry appointments

The new appointments ensure the company is well-placed to deliver on its strategy to become a leading manufacturer of high-quality, EU GMP phytocannabinoid-derived medicine products.

MGC Pharmaceuticals Ltd - MGC Pharmaceuticals strategic appointments strengthen board and leadership team
The company is focused on building a strong leadership team with biopharma industry expertise

MGC Pharmaceuticals Ltd (ASX:MXC) has strengthened its board and leadership team with biopharma industry expertise by making three key appointments aimed at helping to accelerate the company's growth strategy.

Evan Hayes has been appointed as an independent non-executive director and strategic advisor, Sabina Suljaković as qualified person and head of the quality assurance in Slovenia and Amir Polak as chief technology officer and head of pharmaceutical production.

All three appointments bring extensive knowledge of the biopharma industry and are expected to help deliver the company’s strategy to become a leading biopharma company that produces and manufactures high-quality medicinal cannabis products that are available globally.

“Highly valuable experience”

MGC Pharma co-founder and managing director Roby Zomer said: “We are delighted to welcome Evan, Sabina and Amir to MGC Pharmaceuticals and have no doubt their respective experience and expertise will be highly valuable.

“2020 has been a strategically important year for the company and strengthening our leadership team with Evan, Sabina and Amir is a testament to how far the company has come.

“We are focused on building and strengthening our biopharma specific expertise with high-quality people in order to achieve our goals.”

Independent non-executive director

Evan Hayes is a highly experienced board member and brings more than 20 years of commercial and leadership experience within the healthcare and biotechnology sectors.

He is currently the Asia Pacific managing director of Factors Group, Canada’s largest natural health company.

Prior to this, Hayes was the director of sourcing and product development at Australia’s largest natural health company, Blackmores, leading the procurement, technical, new product development, and strategic sourcing divisions and managed a budget of $250 million.

During his career, he has worked across Europe, the USA and in Australia and has strong knowledge of both the FDA and the TGA regulation.

These qualities and experience, mean Hayes is well-placed to serve as an independent non-executive director and strategic advisor to MGC Pharma.

Head of the quality assurance

Sabina Suljaković brings vast experience in quality leadership from her previous managerial roles at leading pharmaceutical companies, including PharmaSwiss (a Bausch Health company).

Her experience will be vital in taking the company to its next phase of growth through serving as qualified person and head of quality assurance in Slovenia.

In these roles, she will ensure the highest quality standards are achieved in order to produce high-quality phytocannabinoid medicine which meets all strict EU regulatory requirements.

Suljaković is also a registered pharmacist at the Ministry of Health and registered qualified person and responsible person at the Slovenian Agency for medicines and medical devices.

Chief technology officer

Amir Polak was previously part of the senior leadership team and co-founder at Green City Ltd, head of chemical production at Nano-Dimension, project co-ordinator for Teva Pharmaceuticals and has been a consultant in the industry for over 10 years.

As chief technology officer and head of pharmaceutical production, Polak will bring extensive production experience to the company and is specialised in ‘Lab to Plant’ development of complex projects.

Quick facts: MGC Pharmaceuticals Ltd

Price: 0.024 AUD

ASX:MXC
Market: ASX
Market Cap: $39.38 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MGC Pharmaceuticals Ltd named herein, including the promotion by the Company of MGC Pharmaceuticals Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Full interview: THC Global Group granted GMP Licence for Southport cannabis...

THC Global Group Limited (ASX:THC) chief executive officer Ken Charteris updates Proactive on being granted a licence to manufacture therapeutic goods for the company’s Southport Facility, known as a GMP Licence, by the Australian Therapeutic Goods Administration (TGA). This milestone...

on 28/1/20

3 min read